Targeting the androgen receptor pathway in prostate cancer

Current Opinion in Pharmacology

Volumn 8, Issue 4, 2008, Pages 440-448

  Chen, Yu ^a   Sawyers, Charles L ^a,b   Scher, Howard I ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANDROGEN; ANDROGEN RECEPTOR; ANTIANDROGEN; ANTINEOPLASTIC AGENT; BICALUTAMIDE; BMS 641988; CYPROTERONE ACETATE; DASATINIB; DEPSIPEPTIDE; DOCETAXEL; DUTASTERIDE; ERLOTINIB; FINASTERIDE; FLUTAMIDE; GEFITINIB; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE INHIBITOR; KETOCONAZOLE; LAPATINIB; MDV 3100; NILUTAMIDE; PANOBINOSTAT; PERTUZUMAB; PHOSPHOTRANSFERASE INHIBITOR; PROSTATE SPECIFIC ANTIGEN; TANESPIMYCIN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ADJUVANT THERAPY; ANDROGEN SYNTHESIS; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER CONTROL; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG RESPONSE; ENZYME ACTIVATION; ENZYME INHIBITION; GENE MUTATION; GENE OVEREXPRESSION; HORMONE ACTION; HORMONE DETERMINATION; HUMAN; LIGAND BINDING; METASTASIS POTENTIAL; NONHUMAN; ONCOGENE; OVERALL SURVIVAL; PANCREAS RESECTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANDROGEN ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS; HISTONE DEACETYLASES; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 51449087794     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2008.07.005     Document Type: Review

References (69)

1. McPhaul M.J. Androgen receptor mutations and androgen insensitivity. Mol Cell Endocrinol 198 (2002) 61-67
2. Yeh S., Tsai M.Y., Xu Q., Mu X.M., Lardy H., Huang K.E., Lin H., Yeh S.D., Altuwaijri S., Zhou X., et al. Generation and characterization of androgen receptor knockout (ARKO) mice: an in vivo model for the study of androgen functions in selective tissues. Proc Natl Acad Sci U S A 99 (2002) 13498-13503
3. Huggins C., and Hodges C.V. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1 (1941) 293-297
4. Smaletz O., and Scher H.I. Outcome predictions for patients with metastatic prostate cancer. Semin Urol Oncol 20 (2002) 155-163
5. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., Oudard S., Theodore C., James N.D., Turesson I., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
6. Petrylak D.P., Tangen C.M., Hussain M.H., Lara Jr. P.N., Jones J.A., Taplin M.E., Burch P.A., Berry D., Moinpour C., Kohli M., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
7. Slovin S.F. Neuroendocrine differentiation in prostate cancer: a sheep in wolf's clothing?. Nat Clin Pract Urol 3 (2006) 138-144
8. Fleming M.T., Morris M.J., Heller G., and Scher H.I. Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials. Nat Clin Pract Oncol 3 (2006) 658-667
9. Kelly W.K., and Scher H.I. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 149 (1993) 607-609
10. Holzbeierlein J., Lal P., LaTulippe E., Smith A., Satagopan J., Zhang L., Ryan C., Smith S., Scher H., Scardino P., et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 164 (2004) 217-227. Authors performed genome-wide expression analysis on clinical prostate cancer specimens and found that many AR-regulated genes that were suppressed when patients initially started hormone ablation therapy are re-expressed upon progression to CRPC. They also found AR and enzymes in androgen synthesis to be frequently overexpressed.
11. Yuan X., Li T., Wang H., Zhang T., Barua M., Borgesi R.A., Bubley G.J., Lu M.L., and Balk S.P. Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells. Am J Pathol 169 (2006) 682-696
12. Chen C.D., Welsbie D.S., Tran C., Baek S.H., Chen R., Vessella R., Rosenfeld M.G., and Sawyers C.L. Molecular determinants of resistance to antiandrogen therapy. Nat Med 10 (2004) 33-39. Authors selected seven prostate cancer xenografts in castrate mice and found that in all the castrate-resistant subclones, AR was overexpressed. Further, forced overexpression was able to confer castrate-resistant growth and converted bicalutamide from an antagonist to an agonist.
13. Gao H., Ouyang X., Banach-Petrosky W.A., Gerald W.L., Shen M.M., and Abate-Shen C. Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. Proc Natl Acad Sci U S A 103 (2006) 14477-14482
14. ••].
15. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.W., Varambally S., Cao X., Tchinda J., Kuefer R., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310 (2005) 644-648. Using bioinformatics tool called 'outlier analysis', Tomlins et al. found that members of the ets transcription factors, including Erg, ETV-1, ETV-5, and ETV-6 were highly overexpressed in a subset of prostate cancers. There are a number of mechanisms of overexpression, including most common fusion with the AR-regulated TMPRSS2 gene.
16. Scher H.I., Buchanan G., Gerald W., Butler L.M., and Tilley W.D. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer 11 (2004) 459-476
17. Scher H.I., and Sawyers C.L. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23 (2005) 8253-8261
18. Feldman B.J., and Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 1 (2001) 34-45
19. Taplin M.E., Rajeshkumar B., Halabi S., Werner C.P., Woda B.A., Picus J., Stadler W., Hayes D.F., Kantoff P.W., Vogelzang N.J., et al. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 21 (2003) 2673-2678
20. Mizokami A., Koh E., Fujita H., Maeda Y., Egawa M., Koshida K., Honma S., Keller E.T., and Namiki M. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res 64 (2004) 765-771
21. Mostaghel E.A., Page S.T., Lin D.W., Fazli L., Coleman I.M., True L.D., Knudsen B., Hess D.L., Nelson C.C., Matsumoto A.M., et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 67 (2007) 5033-5041
22. Stanbrough M., Bubley G.J., Ross K., Golub T.R., Rubin M.A., Penning T.M., Febbo P.G., and Balk S.P. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66 (2006) 2815-2825. Authors compared expression profile of laser dissected primary prostate cancer with that of castrate-resistant bone marrow metastatic disease. They found upregulation of AR and multiple genes involved in androgen synthesis.
23. Montgomery R.B., Mostaghel E.A., Vessella R., Hess D.L., Kalhorn T.F., Higano C.S., True L.D., and Nelson P.S. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68 (2008) 4447-4454. Using mass spectrometry to measure tissue androgen levels, the group found that CRPC tumors in men treated with androgen depletion therapy had higher testosterone levels than primary tumors in untreated men, despite the former group having lower circulation testosterone levels. Using quantitative rtPCR, they found overexpression of a number of key enzymes in androgen synthesis.
24. Bubendorf L., Kononen J., Koivisto P., Schraml P., Moch H., Gasser T.C., Willi N., Mihatsch M.J., Sauter G., and Kallioniemi O.P. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 59 (1999) 803-806
25. Edwards J., Krishna N.S., Grigor K.M., and Bartlett J.M. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 89 (2003) 552-556
26. Yu Y.P., Landsittel D., Jing L., Nelson J., Ren B., Liu L., McDonald C., Thomas R., Dhir R., Finkelstein S., et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 22 (2004) 2790-2799
27. Lapointe J., Li C., Higgins J.P., van de Rijn M., Bair E., Montgomery K., Ferrari M., Egevad L., Rayford W., Bergerheim U., et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A 101 (2004) 811-816
28. Signoretti S., Montironi R., Manola J., Altimari A., Tam C., Bubley G., Balk S., Thomas G., Kaplan I., Hlatky L., et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 92 (2000) 1918-1925
29. Mellinghoff I.K., Vivanco I., Kwon A., Tran C., Wongvipat J., and Sawyers C.L. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 6 (2004) 517-527
30. Mahajan N.P., Liu Y., Majumder S., Warren M.R., Parker C.E., Mohler J.L., Earp H.S., and Whang Y.E. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc Natl Acad Sci U S A 104 (2007) 8438-8443
31. Craft N., Shostak Y., Carey M., and Sawyers C.L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5 (1999) 280-285
32. Hobisch A., Eder I.E., Putz T., Horninger W., Bartsch G., Klocker H., and Culig Z. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 58 (1998) 4640-4645
33. Culig Z., Hobisch A., Cronauer M.V., Radmayr C., Trapman J., Hittmair A., Bartsch G., and Klocker H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54 (1994) 5474-5478
34. Kousteni S., Bellido T., Plotkin L.I., O'Brien C.A., Bodenner D.L., Han L., Han K., DiGregorio G.B., Katzenellenbogen J.A., Katzenellenbogen B.S., et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 104 (2001) 719-730
35. Guo Z., Dai B., Jiang T., Xu K., Xie Y., Kim O., Nesheiwat I., Kong X., Melamed J., Handratta V.D., et al. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 10 (2006) 309-319
36. Kraus S., Gioeli D., Vomastek T., Gordon V., and Weber M.J. Receptor for activated C kinase 1 (RACK1) and Src regulate the tyrosine phosphorylation and function of the androgen receptor. Cancer Res 66 (2006) 11047-11054
37. Migliaccio A., Varricchio L., De Falco A., Castoria G., Arra C., Yamaguchi H., Ciociola A., Lombardi M., Di Stasio R., Barbieri A., et al. Inhibition of the SH3 domain-mediated binding of Src to the androgen receptor and its effect on tumor growth. Oncogene 26 (2007) 6619-6629
38. Scher H.I., Liebertz C., Kelly W.K., Mazumdar M., Brett C., Schwartz L., Kolvenbag G., Shapiro L., and Schwartz M. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol 15 (1997) 2928-2938
39. Fossa S.D., Slee P.H., Brausi M., Horenblas S., Hall R.R., Hetherington J.W., Aaronson N., de Prijck L., and Collette L. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol 19 (2001) 62-71
40. Small E.J., Halabi S., Dawson N.A., Stadler W.M., Rini B.I., Picus J., Gable P., Torti F.M., Kaplan E., and Vogelzang N.J. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 22 (2004) 1025-1033
41. Ryan C.J., Halabi S., Ou S.S., Vogelzang N.J., Kantoff P., and Small E.J. Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study. Clin Cancer Res 13 (2007) 2030-2037
42. Barrie S.E., Potter G.A., Goddard P.M., Haynes B.P., Dowsett M., and Jarman M. Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol 50 (1994) 267-273
43. O'Donnell A., Judson I., Dowsett M., Raynaud F., Dearnaley D., Mason M., Harland S., Robbins A., Halbert G., Nutley B., et al. Hormonal impact of the 17alpha-hydroxylase/C(17-20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 90 (2004) 2317-2325
44. Thomas L.N., Douglas R.C., Lazier C.B., Too C.K., Rittmaster R.S., and Tindall D.J. Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer. Eur Urol 53 (2008) 244-252
45. Shao T.C., Li H., Ittmann M., and Cunningham G.R. Effects of dutasteride on prostate growth in the large probasin-large T antigen mouse model of prostate cancer. J Urol 178 (2007) 1521-1527
46. Xu Y., Dalrymple S.L., Becker R.E., Denmeade S.R., and Isaacs J.T. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res 12 (2006) 4072-4079
47. Solit D.B., and Rosen N. Hsp90: a novel target for cancer therapy. Curr Top Med Chem 6 (2006) 1205-1214
48. Solit D.B., Zheng F.F., Drobnjak M., Munster P.N., Higgins B., Verbel D., Heller G., Tong W., Cordon-Cardo C., Agus D.B., et al. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clin Cancer Res 8 (2002) 986-993
49. Hieronymus H., Lamb J., Ross K.N., Peng X.P., Clement C., Rodina A., Nieto M., Du J., Stegmaier K., Raj S.M., et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 10 (2006) 321-330
50. Modi S., Stopeck A.T., Gordon M.S., Mendelson D., Solit D.B., Bagatell R., Ma W., Wheler J., Rosen N., Norton L., et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 25 (2007) 5410-5417
51. Rosenfeld M.G., Lunyak V.V., and Glass C.K. Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev 20 (2006) 1405-1428
52. Minucci S., and Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6 (2006) 38-51
53. Butler L.M., Agus D.B., Scher H.I., Higgins B., Rose A., Cordon-Cardo C., Thaler H.T., Rifkind R.A., Marks P.A., and Richon V.M. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60 (2000) 5165-5170
54. Rokhlin O.W., Glover R.B., Guseva N.V., Taghiyev A.F., Kohlgraf K.G., and Cohen M.B. Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells. Mol Cancer Res 4 (2006) 113-123
55. Chen L., Meng S., Wang H., Bali P., Bai W., Li B., Atadja P., Bhalla K.N., and Wu J. Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther 4 (2005) 1311-1319
56. Marrocco D.L., Tilley W.D., Bianco-Miotto T., Evdokiou A., Scher H.I., Rifkind R.A., Marks P.A., Richon V.M., and Butler L.M. Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther 6 (2007) 51-60
57. Welsbie DS, Xu J, Chen Y, Borsul L, Scher HI, Rosen R, Sawyers CL: HDACs are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res, in press.
58. Korkmaz C.G., Fronsdal K., Zhang Y., Lorenzo P.I., and Saatcioglu F. Potentiation of androgen receptor transcriptional activity by inhibition of histone deacetylation - rescue of transcriptionally compromised mutants. J Endocrinol 182 (2004) 377-389
59. Mellinghoff I.K., Cloughesy T.F., and Mischel P.S. PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res 13 (2007) 378-381
60. Mellinghoff I.K., Wang M.Y., Vivanco I., Haas-Kogan D.A., Zhu S., Dia E.Q., Lu K.V., Yoshimoto K., Huang J.H., Chute D.J., et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353 (2005) 2012-2024
61. Nagata Y., Lan K.H., Zhou X., Tan M., Esteva F.J., Sahin A.A., Klos K.S., Li P., Monia B.P., Nguyen N.T., et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6 (2004) 117-127
62. Berns K., Horlings H.M., Hennessy B.T., Madiredjo M., Hijmans E.M., Beelen K., Linn S.C., Gonzalez-Angulo A.M., Stemke-Hale K., Hauptmann M., et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12 (2007) 395-402
63. Chen Y, Sawyers CL: Molecular biology of prostate cancer. In Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 8th edition. Edited by Vicent t. Devita Jr, Theodore S. Lawrence, Steven A. Rosenberg, Ronald A. DePinho and Robert A. Weinberg. Lippincott Williams & Wilkins. 2008:1385-1392.
64. Gao H., Ouyang X., Banach-Petrosky W.A., Shen M.M., and Abate-Shen C. Emergence of androgen independence at early stages of prostate cancer progression in nkx3.1; pten mice. Cancer Res 66 (2006) 7929-7933
65. Talpaz M., Shah N.P., Kantarjian H., Donato N., Nicoll J., Paquette R., Cortes J., O'Brien S., Nicaise C., Bleickardt E., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 354 (2006) 2531-2541
66. Gross M., Higano C., Pantuck A., Castellanos O., Green E., Nguyen K., and Agus D.B. A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer 7 (2007) 142
67. Curigliano G., De Braud F., Teresa Sandri M., Renne G., Zorzino L., Scardino E., Rocco B., Spitaleri G., De Pas T., Noberasco C., et al. Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity. Anticancer Drugs 18 (2007) 949-954
68. Ziada A., Barqawi A., Glode L.M., Varella-Garcia M., Crighton F., Majeski S., Rosenblum M., Kane M., Chen L., and Crawford E.D. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 60 (2004) 332-337
69. Agus D.B., Sweeney C.J., Morris M.J., Mendelson D.S., McNeel D.G., Ahmann F.R., Wang J., Derynck M.K., Ng K., Lyons B., et al. Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J Clin Oncol 25 (2007) 675-681